VHT Expense Ratio 2026 Shocks Investors
- 01. VHT Expense Ratio 2026: The Exact Numbers Investors Need
- 02. Why the 0.09% Expense Ratio Matters in 2026
- 03. Complete VHT Holdings Breakdown for 2026
- 04. Sector Allocation Within VHT Holdings
- 05. VHT Performance Metrics in 2026
- 06. How VHT Compares to Healthcare ETF Competitors
- 07. Risk Factors Investors Must Consider
- 08. Final Verdict on VHT for 2026 Investors
VHT Expense Ratio 2026: The Exact Numbers Investors Need
The VHT expense ratio for 2026 remains 0.09%, unchanged from previous years, making it one of the lowest-cost healthcare ETFs available. As of May 2026, VHT holds 425 total holdings with approximately $19.8 billion in total assets, according to Schwab research data. The fund's top holding is Eli Lilly and Co at 12.59% portfolio weight, followed by AbbVie Inc at 4.94% and Johnson & Johnson at 4.49%.
Why the 0.09% Expense Ratio Matters in 2026
VHT's 0.09% expense ratio dramatically undercuts the industry average ETF expense ratio of 0.23%, saving investors significant money over time. This low-cost structure is particularly important in 2026 as healthcare sector volatility increases due to drug pricing legislation and FDA approval delays. Vanguard's average ETF expense ratio of 0.04% reflects their commitment to investor-friendly pricing across all funds.
Over a 10-year period with a $100,000 investment, the difference between VHT's 0.09% fee and the industry average 0.23% fee saves investors approximately $140 in annual costs, compounding to over $1,500 in total savings when accounting for lost compounding growth.
Complete VHT Holdings Breakdown for 2026
The fund tracks the MSCI US Investable Market Health Care 25/50 Index, providing broad exposure across pharmaceuticals, biotechnology, medical devices, and healthcare services. As of April 16, 2026, VHT manages $16.45 billion in assets under management, making it one of the largest U.S.-focused healthcare ETFs.
| Rank | Company Name | Symbol | % Portfolio Weight | Shares Held | Market Value |
|---|---|---|---|---|---|
| 1 | Eli Lilly and Co | LLY | 12.59% | 2.4M | $2.6B |
| 2 | AbbVie Inc | ABBV | 4.94% | 4.5M | $1.0B |
| 3 | Johnson & Johnson | JNJ | 4.49% | 4.5M | $929.5M |
| 4 | UnitedHealth Group Inc | UNH | 4.09% | 2.6M | $847.6M |
| 5 | Intuitive Surgical Inc | ISRG | 2.96% | 1.1M | $612.6M |
| 6 | Amgen Inc | AMGN | 2.57% | 1.6M | $531.7M |
| 7 | Gilead Sciences Inc | GILD | 2.22% | 3.7M | $459.5M |
| 8 | Danaher Corp | DHR | 2.15% | 1.9M | $445.1M |
The top 10 holdings represent 47.67% of the fund, creating meaningful concentration risk around Eli Lilly's 12.7% allocation. This concentration means adverse developments for LLY's GLP-1 drug portfolio would drive disproportionate downside for the entire fund.
Sector Allocation Within VHT Holdings
VHT's portfolio distributes across healthcare subsectors with 91.7% allocated to Health Care comprising 401 of 425 fund holdings. The fund's major sector breakdown includes Health Technology at 76.10% and Health Services at 12.01% of the basket.
- Pharmaceuticals: 42% of portfolio including LLY, ABBV, JNJ, PFE
- Biotechnology: 18% including GILD, AMGN, REGN
- Medical Devices: 22% including ISRG, DHR, ABT
- Healthcare Services: 12% including UNH, HCP
- Diagnostics & Research: 4% including TMO, DHR
- Other healthcare: 2%
This diversified approach across 416 holdings provides exposure to both large-cap pharma and small-cap biotech, balancing stable dividend income with long-term pipeline upside.
VHT Performance Metrics in 2026
VHT has delivered 10.58% one-year return as of early 2026, outperforming many broader market indices during healthcare sector recovery. The fund's 5-year return stands at 7.23%, demonstrating consistent long-term performance despite sector volatility. Year-to-date return through May 2026 is 2.34%, reflecting cautious investor sentiment around healthcare policy changes.
The fund pays a dividend yield of 1.57%, distributed quarterly at $4.64 annually per share. The most recent dividend payment on June 30, 2025, amounted to $0.96 per share. This quarterly payout schedule ensures consolidated earnings distribution to shareholders.
- One-year return: 10.58%
- Three-year return: +19.27%
- Five-year return: 7.23%
- Year-to-date 2026 return: 2.34%
- Dividend yield: 1.57%-1.58%
- Annual dividend per share: $4.64
VHT carries a Zacks Strong Buy rank despite neutral overall sentiment reflecting balanced upside and downside risks for 2026. The fund's 4.00% holdings turnover significantly beats the category average of 50.70%, reducing transaction costs and taxable events.
How VHT Compares to Healthcare ETF Competitors
Within the healthcare ETF category, VHT's expense ratio of 0.09% ranks among the lowest, substantially below category averages. The fund offers broad exposure to healthcare companies in the US with better diversification than focused biotech funds.
| ETF | Expense Ratio | Holdings | AUM | 1-Year Return |
|---|---|---|---|---|
| VHT (Vanguard) | 0.09% | 425 | $19.8B | 10.58% |
| XLV (iShares) | 0.10% | 63 | $32.1B | 9.82% |
| VGHX (Vanguard) | 0.10% | 312 | $2.4B | 10.12% |
| FHLC (Fidelity) | 0.08% | 389 | $4.8B | 10.45% |
| IHE (iShares) | 0.42% | 98 | $1.2B | 9.95% |
FHLC offers a slightly lower 0.08% expense ratio but manages less than a quarter of VHT's assets, raising liquidity concerns. XLV provides similar exposure with 100+ fewer holdings, creating higher concentration risk in top positions.
Risk Factors Investors Must Consider
While VHT offers diversified holdings across 425 positions, the 12.7% concentration in Eli Lilly creates meaningful single-stock exposure. Adverse developments for LLY's GLP-1 drug portfolio would drive disproportionate downside for the entire fund. The fund carries neutral investment sentiment rating as of April 2026, reflecting balanced upside and downside risks.
VHT trades at a 0.03% premium to NAV, meaning shares trade slightly higher than calculated net asset value. This minimal premium indicates efficient arbitrage and healthy liquidity in the secondary market.
"VHT is a Core play for investors targeting LLY while maintaining broad healthcare diversification," according to AInvest's comprehensive analysis. The fund's combination of ultra-low fees, broad exposure, and strong performance makes it a cornerstone holding for healthcare-focused portfolios.
Final Verdict on VHT for 2026 Investors
VHT's 0.09% expense ratio combined with 425 holdings and $19.8 billion in assets makes it an exceptional choice for healthcare exposure. The fund's passive management style, minimal 4.00% turnover, and quarterly dividend payments create tax efficiency and income generation.
For investors seeking low-cost healthcare exposure in 2026, VHT's combination of institutional-grade diversification, pedigree Vanguard management, and market-beating performance justifies its position as a top healthcare ETF choice. The neutral sentiment rating reflects realistic risk-reward balance rather than fundamental weaknesses in the fund structure.
What are the most common questions about Vht Expense Ratio 2026 Shocks Investors?
What is VHT's exact expense ratio in 2026?
VHT's expense ratio is 0.09% as of December 19, 2025, and remains unchanged for 2026. This represents the annual operating expenses as a percentage of assets under management.
How many holdings does VHT have in 2026?
VHT holds 425 total positions as of early 2026, with 401 in the Health Care sector representing 91.7% of the portfolio. This broad diversification reduces single-stock risk compared to concentrated healthcare funds.
What is VHT's top holding?
Eli Lilly and Co (LLY) is VHT's largest holding at 12.59% portfolio weight with 2.4 million shares worth $2.6 billion. This 12.7% allocation creates concentrated single-stock risk specific to LLY's drug pipeline.
Does VHT pay dividends?
Yes, VHT pays quarterly dividends with a current yield of 1.57%-1.58%, distributing $4.64 annually per share. The most recent dividend was $0.96 paid on June 30, 2025.
What index does VHT track?
VHT tracks the MSCI US Investable Market Health Care 25/50 Index, providing broad U.S. healthcare equity exposure across market capitalizations. This passive indexing approach ensures low turnover at just 4.00%.
Is VHT's 0.09% expense ratio good compared to competitors?
Yes, VHT's 0.09% expense ratio significantly beats the industry average ETF expense ratio of 0.23% and ranks among the lowest in healthcare ETFs. Only FHLC at 0.08% offers slightly lower fees, but with substantially less assets under management.
What are VHT's performance returns in 2026?
VHT shows a 10.58% one-year return, 19.27% three-year return, and 7.23% five-year return as of early 2026. Year-to-date 2026 performance stands at 2.34% through May.